oral glp-1 agonist approved FDA just orforglipron (Foundayo), Eli Lilly's receptor for obesity. In the ATTAIN-1 phase 3 trial (n=3,127), published in the New England Journal of Medicine, patients on the highest Novo Nordisk's Wegovy® pill (oral

Bao Y, Jiang L, Chen H, Zou J, Liu Z, Shi Y

Additionally, GLP-1 promotes the growth and proliferation of pancreatic cells, inhibits glucagon secretion, and enhances peripheral tissue uptake of glucose, making it a key factor in maintaining stable blood glucose levels

Bush MA, Matthews JE, De Boever EH, Dobbins RL, Hodge RJ, Walker SE, et al

Results from Phase 2 trials were subsequently halted due to excessive rates of gastrointestinal adverse events leading to participant withdrawals

Insulin is the hormone responsible for helping glucose (sugar) in the bloodstream enter cells, where it can be used for energy or stored

The SURPASS trial (NCT04093752) will compare tirzepatide with liraglutide in high-risk patients with T2DM, while the SURMOUNT MMO study (NCT05556512) will evaluate the impact of tirzepatide on morbidity and mortality in patients with obesity